The STARI (stimulation to activate respiration) trial evaluates the feasibility of the investigational AeroNova system. It looks at the system in patients suffering from moderate to severe Acute Hypoxemic Respiratory Failure (AHRF).

AeroNova, a novel, minimally invasive medical device, delivers continuous diaphragm neurostimulation in tandem with mechanical ventilation. Lungpacer designed it to mitigate the harmful effects of positive-pressure mechanical ventilation. It could reduce the risk of multi-organ ventilator-induced injury.

The investigational AeroNova system includes a cardiovascular catheter embedded with stimulating electrodes. It features a software-controlled system that contracts the diaphragm through transvenous phrenic nerve neurostimulation